TechFlow news, October 9 — According to PR Newswire, biotechnology company Leap Therapeutics (Nasdaq: LPTX) announced the completion of its previously disclosed private placement, raising $58.888888 million in cash led by Winklevoss Capital to launch a digital asset treasury strategy.
Winklevoss Capital will provide Leap with capital and strategic support to help build and execute its digital asset treasury strategy. Proceeds will also continue funding the development of Leap’s therapeutic programs, including FL-501 and sirexatamab. Under the lead investor agreement, Leap’s board of directors will expand to 12 members, with Winklevoss Capital entitled to nominate two directors, one of whom will serve as board chair.
Add to Favorites
Share to Social Media
